Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharmarise HoldingsTSE:2796 46 5-Year Yield-on-Cost % is 2.77 as of Sep. 03, 2026, which is 23% above its 10-year median of 2.25. GuruFocus rates TSE:2796 with a GF Score™ of 46/100 and a GF Value™ of 円581.10 (Modestly Undervalued). The stock has 10 warning signs investors should review. Among 280 Healthcare Providers & Services companies, Pharmarise Holdings ranks worse than 51.43% on this metric.
Pharmarise Holdings's yield on cost for the quarter that ended in May. 2026 was 2.77.
The historical rank and industry rank for Pharmarise Holdings's 5-Year Yield-on-Cost % or its related term are showing as below:
TSE:2796'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.66 Med: 2.25 Max: 2.98
Current: 2.77
During the past 13 years, Pharmarise Holdings's highest Yield on Cost was 2.98. The lowest was 1.66. And the median was 2.25.
TSE:2796's 5-Year Yield-on-Cost % is ranked worse than 51.43% of 280
companies
in the Healthcare Providers & Services industry
Industry Median: 2.98
vs TSE:2796: 2.77
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Pharmarise Holdings 5-Year Yield-on-Cost % Related Terms
For the Pharmaceutical Retailers subindustry, Pharmarise Holdings's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharmarise Holdings 5-Year Yield-on-Cost % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Pharmarise Holdings's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Pharmarise Holdings's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Pharmarise Holdings (TSE:2796) has a 5-Year Yield-on-Cost % of 2.77 as of Sep. 03, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Pharmarise Holdings and its competitors. This is 23% above median its historical median of 2.25. Over the past decade, Pharmarise Holdings' 5-Year Yield-on-Cost % has ranged from 1.66 to 2.98. According to the industry distribution chart, Pharmarise Holdings ranks #144 out of 280 companies in the Healthcare Providers & Services industry, placing it in the top 51.4%.
Is Pharmarise Holdings' 5-Year Yield-on-Cost % too high?
Pharmarise Holdings' current 5-Year Yield-on-Cost % of 2.77 is 23% above median its 10-year median of 2.25. Over the past 10 years, this metric has ranged from a low of 1.66 to a high of 2.98. The Healthcare Providers & Services industry median 5-Year Yield-on-Cost % is 2.98. Pharmarise Holdings' value of 2.77 is 7% below this industry median. Based on the distribution chart, Pharmarise Holdings ranks #144 out of 280 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Pharmarise Holdings has a GF Score™ of 46/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharmarise Holdings' 5-Year Yield-on-Cost % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Pharmarise Holdings ranks #144 out of 280 companies for 5-Year Yield-on-Cost %. This places Pharmarise Holdings in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.98. Pharmarise Holdings' value of 2.77 is 7% below this benchmark. Historically, Pharmarise Holdings' own 5-Year Yield-on-Cost % has ranged from 1.66 to 2.98 over the past decade. While the company's 10-year median is 2.25 vs. the industry median of 2.98, Pharmarise Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Healthcare Providers & Services company?
The median 5-Year Yield-on-Cost % among Healthcare Providers & Services companies is 2.98, based on 280 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharmarise Holdings's current 5-Year Yield-on-Cost % of 2.77 is 7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Pharmarise Holdings and its competitors. For the Healthcare Providers & Services industry, the median 5-Year Yield-on-Cost % is 2.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharmarise Holdings's current 5-Year Yield-on-Cost % is 2.77, which is 23% above median its own 10-year median of 2.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmarise Holdings stock overvalued right now?
Based on GuruFocus' analysis, Pharmarise Holdings (TSE:2796) is currently considered Modestly Undervalued. The stock's GF Value™ is 円581.10, compared to a current price of 円505.00 — trading 13.1% below its estimated fair value. The current 5-Year Yield-on-Cost % is 2.77, which is 23% above median its 10-year median of 2.25 and 7% below the Healthcare Providers & Services industry median of 2.98. Pharmarise Holdings' overall GF Score™ is 46/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Pharmarise Holdings (TSE:2796), the current 5-Year Yield-on-Cost % is 2.77 as of Sep. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharmarise Holdings (TSE:2796) Overvalued in 2026?
Based on GuruFocus' analysis, Pharmarise Holdings stock appears to be undervalued.
The current stock price of 円505.00 is trading 13.1% below its estimated GF Value™ of 円581.10.
GuruFocus considers Pharmarise Holdings to be Modestly Undervalued.
Key valuation signals for TSE:2796:
5-Year Yield-on-Cost %: 2.77 (23% above median its 10-year median of 2.25)
GF Value™: 円581.10 vs. price of 円505.00 (13.1% below fair value)
Industry Position: 7% below the Healthcare Providers & Services median (#144 of 280)
No single metric tells the full story. See the TSE:2796 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharmarise Holdings Corp is engaged in the operation of dispensing pharmacies, which prescribe medicines to general patients based on the prescriptions issued by medical institutions. It is also engaged in the storage and management of medical examination records of patients on behalf of the medical institution.
46GF Score
Get the complete analysis for TSE:2796
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:2796 has been successfully added to your 
